Budesonide bests COVID-19

Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide tw...

Full description

Saved in:
Bibliographic Details
Published in:Canadian family physician 2022-05, Vol.68 (5), p.355-355
Main Authors: Moe, Samantha S, Allan, G Michael, Train, Anthony
Format: Article
Language:English
Subjects:
Antiretroviral drugs
Antiviral drugs
Bronchodilator Agents
Budesonide - therapeutic use
Clinical outcomes
Clinical trials
COVID-19
Family physicians
Hospitalization
Humans
Monoclonal antibodies
SARS-CoV-2
Steroids
Tools for Practice
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Moe et al examine the effect of inhaled corticosteroids on length of illness, emergency department visits, and hospital admissions in outpatients with COVID-19. Based on 2 open-label trials, higher-risk outpatients with suspected or confirmed COVID-19 may benefit from 800 pg of inhaled budesonide twice a day for 14 days. Compared with usual care, budesonide shortened the time to recovery, increased the proportion of patients recovering by day 14, and reduced the need for health services. Outpatients with COVID-19 have a growing number of treatments available to them. Antiviral agents (nirmatrelvir-ritonavir) and monoclonal antibodies (eg, sotrovimab) appear to reduce the risk of death or hospitalization, but patient eligibility and access vary by jurisdiction. Family physicians can provide inhaled budesonide at the point of care to those not eligible for antiviral agents or monoclonal antibodies. Fluvoxamine is also available, but its benefits are less certain than those of other treatments.
ISSN:0008-350X
1715-5258
DOI:10.46747/cfp.6805355